{"id":4999,"date":"2021-09-19T17:49:59","date_gmt":"2021-09-19T14:49:59","guid":{"rendered":"https:\/\/www.klimik.org.tr\/koronavirus\/?p=4999"},"modified":"2021-09-20T17:52:16","modified_gmt":"2021-09-20T14:52:16","slug":"koronavirusa-karsi-2-doz-asi-yeterli-mi-3-doz-ya-da-hatirlatma-dozu-icin-kim-ne-tavsiye-ediyor","status":"publish","type":"post","link":"https:\/\/www.klimik.org.tr\/koronavirus\/koronavirusa-karsi-2-doz-asi-yeterli-mi-3-doz-ya-da-hatirlatma-dozu-icin-kim-ne-tavsiye-ediyor\/","title":{"rendered":"Koronavirusa Kar\u015f\u0131 2 Doz A\u015f\u0131 Yeterli mi? 3. Doz ya da Hat\u0131rlatma Dozu \u0130\u00e7in Kim Ne Tavsiye Ediyor?"},"content":{"rendered":"

\"\"COVID-19 a\u015f\u0131lar\u0131n\u0131n zamanla etkinli\u011fini kaybetmesi ve Delta varyant\u0131 gibi daha tehlikeli ve bula\u015f\u0131c\u0131 viruslar kar\u015f\u0131s\u0131nda ABD ve \u0130srail gibi \u00fclkelerde, ya\u015fl\u0131 veya risk grubunda olanlara \u00fc\u00e7\u00fcnc\u00fc doz g\u00fc\u00e7lendirici a\u015f\u0131 vurulmaya ba\u015fland\u0131. Peki g\u00fc\u00e7lendirici a\u015f\u0131 dozlar\u0131 ne kadar gerekli? Neden baz\u0131 bilim insanlar\u0131 ve D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc \u00fc\u00e7\u00fcnc\u00fc doz a\u015f\u0131n\u0131n yayg\u0131nla\u015fmas\u0131na kar\u015f\u0131 \u00e7\u0131k\u0131yor?<\/strong><\/p>\n

Ara\u015ft\u0131rmalar ve veriler g\u00fc\u00e7lendirici a\u015f\u0131 hakk\u0131nda ne diyor?<\/strong><\/p>\n

ABD’li Pfizer ve Alman orta\u011f\u0131 BioNTech \u015firketleri, ba\u015flang\u0131\u00e7ta semptomatik COVID-19 infeksiyonuna kar\u015f\u0131 y\u00fczde 90’\u0131n \u00fczerinde oldu\u011fu tahmin edilen a\u015f\u0131lar\u0131n\u0131n etkinli\u011finin zamanla azald\u0131\u011f\u0131n\u0131 g\u00f6steren yeni ara\u015ft\u0131rmalar sundu.<\/p>\n

Sonu\u00e7 olarak, pandemi s\u0131ras\u0131nda daha \u00f6nce a\u015f\u0131lanan ki\u015filerin, \u00f6zellikle h\u0131zla yay\u0131lan Delta varyant\u0131 kar\u015f\u0131s\u0131nda daha savunmas\u0131z oldu\u011fu ortaya \u00e7\u0131kt\u0131. \u0130la\u00e7 \u00fcreticileri, 3. doz g\u00fc\u00e7lendirici dozlar\u0131n iki doz a\u015f\u0131lama taraf\u0131ndan \u00fcretilen antikorlar\u0131n azalan seviyelerini geri kazanmaya yard\u0131mc\u0131 oldu\u011funu s\u00f6yledi.<\/p>\n

COVID-19 a\u015f\u0131s\u0131 \u00fcreten bir di\u011fer ABD’li ila\u00e7 firmas\u0131 Moderna da bu hafta yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, 13 ay \u00f6nce iki dozluk a\u015f\u0131 yapt\u0131ranlarda, sekiz ay \u00f6nce a\u015f\u0131lananlara k\u0131yasla daha y\u00fcksek infeksiyon oran\u0131 oldu\u011funu ifade etti. Yani Moderna a\u015f\u0131s\u0131nda da zamanla antikor seviyesi azal\u0131yor.<\/p>\n

Pfizer: Her iki ayda a\u015f\u0131n\u0131n etkinli\u011fi y\u00fczde 6 azal\u0131yor<\/strong><\/p>\n

Pfizer’in 30 bin ki\u015filik klinik denemesinden elde edilen veriler, a\u015f\u0131n\u0131n etkinli\u011finin ikinci dozdan sonra her iki ayda bir yakla\u015f\u0131k y\u00fczde 6 oran\u0131nda azald\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Pfizer’in 300 kat\u0131l\u0131mc\u0131da ikinci bir deneme testi ise, \u00fc\u00e7\u00fcnc\u00fc bir dozun, ikinciden daha iyi bir ba\u011f\u0131\u015f\u0131kl\u0131k sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6sterdi.<\/p>\n

ABD sa\u011fl\u0131k d\u00fczenleyicileri ayr\u0131ca, n\u00fcfusun \u00e7o\u011funlu\u011funun Pfizer\/BioNTech a\u015f\u0131s\u0131n\u0131 ald\u0131\u011f\u0131 \u0130srail’den a\u015f\u0131 etkinli\u011fi ve g\u00fc\u00e7lendiricilere ili\u015fkin verileri yak\u0131ndan izliyor. \u0130srail’de 12 ya\u015f ve \u00fcst\u00fc herkese destekleyici \u00fc\u00e7\u00fcnc\u00fc doz a\u015f\u0131 yapt\u0131r\u0131l\u0131yor.<\/p>\n

\u0130srail’de 60 ya\u015f \u00fcst\u00fc olanlara 3. doz a\u015f\u0131 var<\/strong><\/p>\n

\u0130srail Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 bu hafta, 60 ya\u015f ve \u00fczeri 1,1 milyondan fazla insan\u0131n bir takviye dozu Pfizer ald\u0131\u011f\u0131n\u0131 ve bu gruptaki COVID-19 kaynakl\u0131 ciddi hastal\u0131klar\u0131n yan\u0131 s\u0131ra genel infeksiyonlarda d\u00fc\u015f\u00fc\u015fe yol a\u00e7t\u0131\u011f\u0131n\u0131 g\u00f6steren verileri duyurdu. Ara\u015ft\u0131rmac\u0131lar destekleyici dozun a\u015f\u0131 etkinli\u011fini y\u00fczde 95’e geri y\u00fckseltebilece\u011fini \u00f6ne s\u00fcr\u00fcyor.<\/p>\n

Ayr\u0131ca, ABD ve \u0130srail’deki baz\u0131 sa\u011fl\u0131k yetkilileri, ciddi hastal\u0131klar\u0131 \u00f6nlemenin yan\u0131 s\u0131ra, bir\u00e7ok \u00fclkede infeksiyon oranlar\u0131n\u0131n artt\u0131\u011f\u0131 bir zamanda takviye dozlar\u0131n\u0131n koronavirusun bula\u015fmas\u0131n\u0131 azaltmaya yard\u0131mc\u0131 olabilece\u011fini savunuyor.<\/p>\n

G\u00fc\u00e7lendirici a\u015f\u0131 dozuna gelen ele\u015ftiriler<\/strong><\/p>\n

Pek \u00e7ok a\u015f\u0131 uzman\u0131, \u015fu ana kadarki verilerin yaln\u0131zca ya\u015fl\u0131lar ve ba\u011f\u0131\u015f\u0131kl\u0131k sistemi zay\u0131f olan ki\u015filerde g\u00fc\u00e7lendiricilere ihtiya\u00e7 oldu\u011funu g\u00f6sterdi\u011fini s\u00f6yl\u00fcyor. Hatta ABD, \u00fc\u00e7\u00fcnc\u00fc doz a\u015f\u0131 plan\u0131n\u0131 a\u00e7\u0131klad\u0131\u011f\u0131nda FDA’da g\u00f6rev yapan iki bilim insan\u0131 istifa etti.<\/p>\n

\u0130srail Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131’n\u0131n bir raporu, 50-59 ve 40-49 ya\u015flar\u0131 aras\u0131ndakilere k\u0131yasla, 60 ya\u015f \u00fcst\u00fc a\u015f\u0131l\u0131 ki\u015filerde ciddi bula\u015f\u0131c\u0131 infeksiyon riskinin \u00e7ok daha y\u00fcksek oldu\u011funu g\u00f6steriyor.<\/p>\n

ABD’deki di\u011fer ara\u015ft\u0131rmalar, iki doz a\u015f\u0131n\u0131n 65 ya\u015f\u0131n alt\u0131ndaki yeti\u015fkinlerde ciddi hastal\u0131k ve \u00f6l\u00fcmlere kar\u015f\u0131 olduk\u00e7a koruyucu oldu\u011funu g\u00f6steriyor.<\/p>\n

Ayr\u0131ca \u00fcnl\u00fc bilim dergilerinden The Lancet’te yay\u0131nlanan ve DS\u00d6’ye ba\u011fl\u0131 ara\u015ft\u0131rmac\u0131lar\u0131n da kat\u0131ld\u0131\u011f\u0131 \u00e7al\u0131\u015fmaya g\u00f6re, COVID-19’un daha \u015fiddetli \u00e7e\u015fitlerine kar\u015f\u0131 iki doz a\u015f\u0131n\u0131n yeterli oldu\u011fu belirtildi.<\/p>\n

Lancet’in ara\u015ft\u0131rmas\u0131n\u0131n vard\u0131\u011f\u0131 sonuca g\u00f6re varyantlar a\u015f\u0131lar\u0131n sa\u011flad\u0131\u011f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 a\u015facak kadar geli\u015fmi\u015f durumda de\u011fil.<\/p>\n

\u00c7al\u0131\u015fman\u0131n yazarlar\u0131 varyantlar\u0131n bu ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 a\u015fmas\u0131 durumunda \u00fc\u00e7\u00fcnc\u00fc doz a\u015f\u0131lar yerine bu varyantlara kar\u015f\u0131 haz\u0131rlanm\u0131\u015f a\u015f\u0131 \u00e7e\u015fitlerinin kullan\u0131lmas\u0131n\u0131n daha do\u011fru oldu\u011funu belirtiyor.<\/p>\n

Birle\u015fik Krall\u0131k, Fransa ve Almanya dahil olmak \u00fczere baz\u0131 \u00fclkeler, ya\u015fl\u0131 yeti\u015fkinler ve di\u011fer y\u00fcksek riskli gruplar i\u00e7in \u015fimdiye kadar s\u0131n\u0131rl\u0131 say\u0131da 3’nc\u00fc doz a\u015f\u0131 vurdu. Bunu genel topluma yayma gibi bir \u00f6ncelik bulunmuyor.<\/p>\n

DS\u00d6’den uyar\u0131: D\u00fcnyada a\u015f\u0131 olamayan \u00e7ok insan var<\/strong><\/p>\n

Bir di\u011fer ele\u015ftiri noktas\u0131 ise, d\u00fcnya genelindeki a\u015f\u0131lanma sorunu. D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc, ABD ve di\u011fer zengin \u00fclkelere, takviye a\u015f\u0131lar\u0131 teklif etmeyi b\u0131rakmalar\u0131 ve bu dozlar\u0131, d\u00fcnya \u00e7ap\u0131nda hen\u00fcz ilk dozlar\u0131n\u0131 almayan bir\u00e7ok insan\u0131 a\u015f\u0131lamaya yard\u0131mc\u0131 olmak i\u00e7in kullanmalar\u0131 i\u00e7in defalarca \u00e7a\u011fr\u0131da bulundu. Ancak bu konuda herhangi bir olumlu yan\u0131t alamad\u0131.<\/p>\n

D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc Ba\u015fkan\u0131 Tedros Adhanom Ghebreyesus da sene sonuna \u00fclkelere ek doz a\u015f\u0131 yapmamalar\u0131 \u00e7a\u011fr\u0131s\u0131nda bulundu.<\/p>\n

Birle\u015fmi\u015f Milletler’e ba\u011fl\u0131 \u00f6rg\u00fct, ay sonuna kadar her \u00fclkenin n\u00fcfusunun en az y\u00fczde 10’unu, sene sonuna kadar da en az y\u00fczde 40’\u0131n\u0131 a\u015f\u0131lamas\u0131n\u0131 hedefliyor. Gelecek senenin ortas\u0131na kadar bu oran\u0131n ise y\u00fczde 70’e ula\u015fmas\u0131 planlan\u0131yor. Bununla birlikte Tedros y\u00fczde 10’luk hedefe d\u00fc\u015f\u00fck gelirli bir \u00fclkenin bile hen\u00fcz ula\u015famad\u0131\u011f\u0131n\u0131n alt\u0131n\u0131 \u00e7iziyor.<\/p>\n

Haber \u0130\u00e7in T\u0131klay\u0131n\u0131z<\/strong><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

COVID-19 a\u015f\u0131lar\u0131n\u0131n zamanla etkinli\u011fini kaybetmesi ve Delta varyant\u0131 gibi daha tehlikeli ve bula\u015f\u0131c\u0131 viruslar kar\u015f\u0131s\u0131nda ABD ve \u0130srail gibi \u00fclkelerde, ya\u015fl\u0131 veya risk grubunda olanlara \u00fc\u00e7\u00fcnc\u00fc doz g\u00fc\u00e7lendirici a\u015f\u0131 vurulmaya ba\u015fland\u0131. Peki g\u00fc\u00e7lendirici a\u015f\u0131 dozlar\u0131 ne kadar gerekli? Neden baz\u0131 bilim insanlar\u0131 ve D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc \u00fc\u00e7\u00fcnc\u00fc doz a\u015f\u0131n\u0131n yayg\u0131nla\u015fmas\u0131na kar\u015f\u0131 \u00e7\u0131k\u0131yor? Ara\u015ft\u0131rmalar ve veriler g\u00fc\u00e7lendirici a\u015f\u0131 hakk\u0131nda ne diyor? ABD’li Pfizer ve Alman orta\u011f\u0131 BioNTech \u015firketleri, ba\u015flang\u0131\u00e7ta semptomatik COVID-19 infeksiyonuna kar\u015f\u0131 y\u00fczde 90’\u0131n \u00fczerinde oldu\u011fu tahmin edilen a\u015f\u0131lar\u0131n\u0131n etkinli\u011finin zamanla azald\u0131\u011f\u0131n\u0131 g\u00f6steren yeni ara\u015ft\u0131rmalar sundu. Sonu\u00e7 olarak, pandemi s\u0131ras\u0131nda daha \u00f6nce a\u015f\u0131lanan ki\u015filerin, \u00f6zellikle h\u0131zla yay\u0131lan Delta varyant\u0131 kar\u015f\u0131s\u0131nda […]<\/p>\n","protected":false},"author":4,"featured_media":5000,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/4999"}],"collection":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/comments?post=4999"}],"version-history":[{"count":1,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/4999\/revisions"}],"predecessor-version":[{"id":5001,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/4999\/revisions\/5001"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media\/5000"}],"wp:attachment":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media?parent=4999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/categories?post=4999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/tags?post=4999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}